Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
40.28B
Market cap40.28B
Price-Earnings ratio
71.53
Price-Earnings ratio71.53
Dividend yield
Dividend yield
Average volume
1.38M
Average volume1.38M
High today
$309.28
High today$309.28
Low today
$301.00
Low today$301.00
Open price
$304.54
Open price$304.54
Volume
1.05M
Volume1.05M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$273.11
52 Week low$273.11

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $301.67. The company's market cap stands at 40.28B, with a P/E ratio of 71.53.

On 2026-07-02, Alnylam Pharmaceuticals(ALNY) stock traded between a low of $301.00 and a high of $309.28. Shares are currently priced at $301.67, which is +0.2% above the low and -2.5% below the high.

Alnylam Pharmaceuticals(ALNY) shares are trading with a volume of 1.05M, against a daily average of 1.38M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $273.11.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $273.11.

ALNY News

Simply Wall St 13h
July 2026's Top Stocks Estimated To Be Trading Below Their Intrinsic Value

The United States market has shown robust performance recently, with a 1.9% increase over the last week and a 20% rise over the past year, while earnings are pr...

July 2026's Top Stocks Estimated To Be Trading Below Their Intrinsic Value
Simply Wall St 18h
How Investors May Respond To Alnylam Pharmaceuticals Expanding Its Enterprise-Wide AI Analytics Partnership

Komodo Health recently announced an expanded strategic partnership with Alnylam Pharmaceuticals to scale its Marmot analytics AI platform across Alnylam’s enter...

How Investors May Respond To Alnylam Pharmaceuticals Expanding Its Enterprise-Wide AI Analytics Partnership
TipRanks 3d
Alnylam price target lowered to $470 from $510 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Alnylam (ALNY) to $470 from $510 and keeps a Buy rating on the shares. The firm reduced its near-term estimat...

Analyst ratings

71%

of 31 ratings
Buy
71%
Hold
29%
Sell
0%

More ALNY News

TipRanks 6d
Alnylam: Buy Rating Reaffirmed as Differentiated RNAi Pipeline and Upcoming Catalysts Support Unchanged $550 Price Target

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Alnylam Pharma, retaining the price target of $550.00. Unlock powerful investing tools and...

TipRanks 7d
Komodo expands strategic partnership with Alnylam

Komodo Health announced an expanded strategic partnership with Alnylam (ALNY) Pharmaceuticals. Built on the Healthcare Map, Marmot, Komodo’s analytics AI platfo...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.